Thus, blocking TGF-β-promoted ERK-1/2 activity might be a straightforward approach to inhibit NSCLC metastasis, in particular in patients with high RAF-1 and TGF-β levels. Here, MAPK3 is linked to non-small cell lung carcinoma.